EP0582643A1 - Acides acetiques de pyridazinone - Google Patents

Acides acetiques de pyridazinone

Info

Publication number
EP0582643A1
EP0582643A1 EP92910955A EP92910955A EP0582643A1 EP 0582643 A1 EP0582643 A1 EP 0582643A1 EP 92910955 A EP92910955 A EP 92910955A EP 92910955 A EP92910955 A EP 92910955A EP 0582643 A1 EP0582643 A1 EP 0582643A1
Authority
EP
European Patent Office
Prior art keywords
methyl
oxo
dihydro
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92910955A
Other languages
German (de)
English (en)
Inventor
Banavara L. Mylari
William J. Zembrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0582643A1 publication Critical patent/EP0582643A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention relates to novel pyridazinone acetic acids and derivatives thereof which are aldose reductase inhibitors and which are useful in the treatment of certain chronic complications arising from diabetes mellitus, such as diabetic cataracts, retinopathy, nephropathy and neuropathy. These compounds can also be used as hypouricemic agents, useful for lowering blood uric acid levels.
  • the invention further relates to novel pharmaceutical compositions containing such compounds and to a method of using these compounds.
  • U.S. Patent No. 3,821,383 discloses aldose reductase inhibitors like 1,3-dioxo-1H-benz-[d,e]-isoquinoline-2-(3H)-acetic acid and derivatives thereof to be useful for the treatment of chronic complications of diabetes.
  • U.S. Patent 4,226,875 teaches the use of spiro-oxazolidinediones for treating complications of diabetes as aldose reductase inhibitors.
  • Such aldose reductase inhibitors function by inhibiting the activity of the enzyme aldose reductase, which is primarily responsible for regulating the reduction of aldoses, such as glucose and galactose, to the corresponding polyols, such as sorbitol and galactitol, in humans and other animals. In this way, unwanted accumulations of galactitol in the lens of galactosemic subjects and of sorbitol in the lens, peripheral nerves and kidneys of various diabetic subjects are prevented or reduced.
  • aldose reductase which is primarily responsible for regulating the reduction of aldoses, such as glucose and galactose
  • polyols such as sorbitol and galactitol
  • such compounds are of therapeutic value as aldose reductase inhibitors for controlling certain chronic diabetic complications, including those of an ocular nature, since it is known in the art that the presence of polyols in the lens of the eye leads to cataract formation, with a concomitant loss of lens clarity.
  • French Patent Publication No. 2647676 relates to pyridazinone derivatives having substituted benzyl side chains and benzothiazole side chains which are described as being inhibitors of aldose reductase.
  • U.S. Patent 4,251,528 discloses aromatic carbocyclic oxophthalazinyl acetic acids having aldose reductase inhibiting properties.
  • Heterocyclic oxophthalazinyl acetic acids and their ethyl esters having an effect on the blood clotting system are disclosed in Chemical Abstracts 1970, 73, 77173y.
  • U.S. Patent No. 4,939,140 is directed to heterocyclic oxophthalazinyl acetic acids.
  • U. S. Patent No. 4,868,301 is directed to processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains.
  • U. S. Patent No. 4,996,204 is directed to Pyridopyridazinone acetic acids.
  • European Patent Publication No. 0,397,350 is directed to a process and intermediates for the preparation of oxophthalazinyl acids and analogs thereof.
  • PCT/US89/05637 relates to substituted oxophthalazinyl acetic acids and analogs thereof.
  • the present invention relates to a compound of the formula
  • X is CH 2 , CH 2 CH 2 , -CH(CH 3 ) or
  • R 1 is an optionally substituted group selected from phenyl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, thiazolopyridin-2-yl, oxazolopyridin-2-yl, 3-phenyl 1,2,4-oxadiazol-5-yl, and 5-phenyl-1,2,4-oxadiazol-3-yl wherein said substituted groups are substituted with one or two substituents that are independently selected from fluorine, chlorine, bromine, methyl, methylthio, methoxy, hydroxy and trifluoromethyl;
  • R 2 and R 3 are independently selected from hydrogen, fluorine, chlorine, bromine, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkoxy and trifluoromethyl or R 2 and R 3 taken together with the carbons to which they are attached form a group W, wherein W is
  • U 1 and U 2 are independently CH 2 , 0 or S with the proviso that both U 1 and U 2 are not O or S;
  • R 4 is hydrogen, or a prodrug group
  • the present invention also relates to the pharmaceutically acceptable salts of the compounds of formula I.
  • Such pharmaceutically acceptable salts include sodium, potassium, calcium and ammonium and those derived from lower alkylamines (e.g. ethylamine), lower alkanolamines (e.g. triethanolamine) and meglumine.
  • Specific preferred compounds of the invention are: 3,4-Dihydro-4-oxo-5,6-dimethyl-3-[(5,7 difluoro-2-benzothiazolyl)methyl]-1-pyridazineacetic acid; 3,4-Dihydro-4-oxo-5,6-dimethyl-3-[(5-trifluoromethyl)- 2-benzothiazoly)methyl]-1-pyridazineacetic acid;
  • the present invention also relates to compounds which are useful as intermediates for preparing the compounds of formula I having the general formula:
  • R 5 is hydrogen or XR 1 wherein
  • X is CH 2 , CH 2 CH 2 , -CH(CH 3 ) , and
  • R 1 is CN, or an optionally substituted group
  • substituted groups are substituted with one or two substitutents that are independently selected from fluorine, chlorine, bromine, methyl, and trifluoromethyl;
  • R 2 and R 3 are independently selected from hydrogen, (C 1 -C 4 ) alkyl, fluorine, chlorine, bromine, and trifluoromethyl or R 2 and R 3 taken together with the carbons to which they are attached form a group W, wherein W is
  • p is 1 or 2 and U 1 and U 2 are independently CH 2 , O or S with the proviso that both U 1 and U 2 are not o or S; and R 4 is (C 1 -C 4 ) alkyl.
  • the present invention also relates to a pharmaceutical composition for inhibition of aldose reductase activity comprising a compound of formula I or a pharmaceutically acceptable salt thereof in an amount effective in the inhibition of aldose reductase activity, in admixture with a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for inhibition of aldose reductase activity comprising a compound of formula I or a pharmaceutically acceptable salt thereof in an amount effective in the inhibition of aldose reductase activity, in admixture with a pharmaceutically acceptable carrier.
  • Specific and preferred compositions contain the specific and preferred compounds of formula I as described above.
  • the present invention further relates to a method of treating a diabetic host such as an animal or a human for diabetes-associated complications which comprises administering to the host an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
  • a diabetic host such as an animal or a human for diabetes-associated complications
  • Specific and preferred methods comprise administering specific and preferred compounds of formula I as described above.
  • the present invention further relates to a pharmaceutical composition which can be used for lowering blood uric acid levels in mammals, e.g., humans comprising a compound of formula I or a pharmaceutically acceptable salt thereof in an amount effective for lowering blood uric acid levels in a admixture with a pharmaceutically acceptable carrier.
  • the present invention also relates to a method of lowering blood uric acid levels in a mammalian subject which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
  • Specific and preferred methods comprise administering specific and preferred compounds of formula I as described above.
  • alkyl includes linear branched and cyclic groups as well as groups having both linear and cyclic or branched and cyclic portions.
  • prodrug as used in the definition of R 4 denotes a group that is converted in vivo resulting in replacement by hydrogen.
  • groups are generally known in the art and include ester forming groups, to form an ester prodrug, such as benzyloxy, di(C 1 -C 4 ) alkyl amino ethyloxy.
  • the compounds of the present invention are prepared as outlined in the following reaction scheme.
  • Anhydrides of formula 1,4 and 8 are either commercially available or may be prepared according to standard procedures.
  • the compounds of formula 2 wherein R 3 is ethyl or t-butyl are prepared by reacting the compounds 1 with (t-butoxycarbonylmethylene)triphenylphosphorane or (carbothoxymethylene) triphenylphosphorane, respectively, in the Wittig reaction described in Tetrahedron Letters, 1965, 2537.
  • the compounds of formula 5 may also be prepared by the same procedure.
  • the compounds of formula 9 are obtained using standard Reformatsky reaction conditions with zinc or zinc-copper couple or using a variety of well-known modifications of the Reformatsky reaction (see, for example, Tetrahedron Letters, 1984, 2569).
  • Suitable solvents for the conversion of 8 to 9 include aromatic hydrocarbons (e.g., benzene) and dialkyl ethers and cyclic ethers (e.g., tetrahydrofuran).
  • the temperature is preferably maintained at about 35°C to about 100°C, more preferably at reflux.
  • a compound of the formula 6 is prepared by standard allylic bromination using N-bromosuccinic in refluxing carbon tetrachloride.
  • the compounds of formula 3 are prepared by reacting the compounds of formula 2, 6 or 9 with anhydrous or aqueous hydrazine in an alcoholic solvent (e.g., ethanol) at a temperature of about 20°C to about 80°C, preferably about 60°C.
  • an alcoholic solvent e.g., ethanol
  • the temperature may be room temperature or the reflux temperature of the solvent.
  • the compounds of formula 13 are obtained on reacting compounds of formula 3 with L-X-R 1 wherein L is chloro or bromo.
  • the process is generally carried out in a polar solvent such as an alkanol having one to four carbon atoms (e.g. methanol or ethanol), dimethylformamide or dimethylsulfoxide, in the presence of a base.
  • a polar solvent such as an alkanol having one to four carbon atoms (e.g. methanol or ethanol), dimethylformamide or dimethylsulfoxide
  • Suitable bases are alkali metal hydrides or alkoxides of one to four carbon atoms, such as sodium or potassium hydride, methoxide or ethoxide.
  • a non-aqueous solvent such as dimethylformamide is required.
  • the reaction is run at room temperature, or at higher temperatures (about 100°C) to accelerate the process.
  • the compounds of formula 11 wherein R 1 is phenyl with hydroxy groups are prepared by demethylating the corresponding methoxy groups. Demethylation is effected by refluxing hydrobromic acid or borontribromide in methylene chloride at a temperature between about -70°C and about 0°C. The preferred temperature is between about -20°C and about 0°C.
  • the compounds of formula 11 wherein X is CH 2 , CH 2 CH 2 or -CH(CH 3 ) and R 1 is optionally substituted benzothiazole are also prepared via the compounds of formula 13.
  • the compounds of formula 13 wherein X is CH 2 , CH 2 CH 2 , or -CH(CH 3 ) and R 1 is CN are prepared by reacting compounds of formula 3 with L 1 -X-R 1 (wherein L 1 is Cl or Br) in the presence of a base.
  • Suitable bases are alkali metal hydrides or alkoxides of one to four carbon atoms.
  • Suitable solvents for the reaction include non-aqueous solvents such as dimethylformamide and dimethylsulfoxide.
  • the reaction is conducted in a polar solvent. Suitable solvents include sulfolane, pyridine and N-methyl pyrrolidone. The preferred solvent is dimethylformamide.
  • the reaction temperature is generally between about 110°C and about 180°C, preferably the reflux temperature of the solvent.
  • the compound of formula 13 wherein R 1 is CN is reacted with the compound of formula 14 in the presence of a tertiary amine. Suitable tertiary amines are tri-(C 2 - C 6 )alkylamines, e.g. triethylamine. These procedures are also applicable to the preparation of compounds wherein R 1 is thiazolopyridine.
  • reaction is conducted in dimethylformamide.
  • reaction is conducted at temperatures between about ambient temperature (generally, about 25°C) and about 100°C.
  • reaction temperature is between about 40 and about 60°C.
  • Compounds of formula 11 wherein X is are prepared by reacting compounds of formula 11 wherein X is with phosphorous pentasulfide in aromatic hydrocarbon solvents such as benzene, toluene or xylenes. The reaction is run at between room temperature and 100°C, preferably at between 40-60oC. The compounds of formula 11 may be hydrolyzed to obtain compounds of formula 12. The hydrolysis is carried out in the presence of concentrated sulfuric acid or trifluoroacetic acid when R 4 is t-butyl at about 0°C to room temperature. When R 4 is methyl or ethyl, the hydrolysis proceeds at conventional temperatures and in the presence of acid or base such as mineral acid, for example hydrochloric acid, or an alkali metal hydroxide such as sodium or potassium hydroxide.
  • acid or base such as mineral acid, for example hydrochloric acid, or an alkali metal hydroxide such as sodium or potassium hydroxide.
  • reaction pressures will be in the range of about 0.5 to 2 atmospheres, preferably ambient pressure (about one atmosphere).
  • the pharmaceutically acceptable salts of compounds of the formula I may be formed with pharmaceutically acceptable cations by conventional methods.
  • these salts may be readily prepared by treating the compound of formula I with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure.
  • a lower alkyl alcohol solution of the compound of formula I may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.
  • Suitable pharmaceutically acceptable cations for this purpose include, but are not limited to, alkali metal cations such as potassium and sodium, ammonium or water-soluble amine addition salts such as N-methylglucamine(meglumine), the lower alkanolammonium and other base salts with organic amines which are pharmaceutically acceptable, and alkaline earth metal cations such as calcium and magnesium.
  • the compounds of formula I and the pharmaceutically acceptable salts thereof are useful as inhibitors of the enzyme aldose reductase in the treatment of chronic complications of diabetes, such as diabetic cataracts, retinopathy nephropathy and neuropathy.
  • the active compounds can also be used for lowering blood uric acid levels in mammals, e.g. humans.
  • Uric acid containing deposits also known as trophi
  • resulting from unphysiologically elevated plasma uric acid levels tend to occur in various tissues throughout the body, leading to the disease condition known as gout and gouty arthritis.
  • Uric acid containing deposits in such conditions may occur in cartilage, bone, bursae, tendons, connective tissue overlying bony prominences, as well as, subcutaneously and in the area of kidney. Elevated blood uric acid levels also occur in number of other disease conditions including myeloid leukemia, myeloid dysplasia, pernicious anemia, psoriasis, diabetes mellitus and renal disease. As used in the claims and specification hereof, treatment is meant to include both the prevention and alleviation of such conditions.
  • the active compounds may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, parenterally and topically.
  • these compounds will be administered orally or parenterally at dosages between about 2 and 100 mg/kg body weight of the subject to be treated per day, preferably from 5 to 50 mg/kg per day. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate does for the individual subject.
  • the active compounds may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
  • suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
  • the pharmaceutical compositions formed by combining the active compounds and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • solutions of an active compound in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • the active compounds may not only be advantageously employed for the preparation of aqueous pharmaceutical compositions for parenteral administration, as described above, but also for the preparation of pharmaceutical compositions suitable for use as ophthalmic solutions.
  • Such ophthalmic solutions are of principal interest for the treatment of diabetic cataracts by topical administration and the treatment of such conditions in this manner is a preferred embodiment of the present invention.
  • the active compounds of this invention are administered to the eye of an ophthalmic preparation prepared in accordance with conventional pharmaceutical practice, see for example "Remington's Pharmaceutical Sciences” 15th Edition, pages 1488 to 1501 (Mack Publishing Co., Easton, Pa).
  • the ophthalmic preparation will contain an active compound in a concentration from about 0.01 to about 1% by weight, preferably from about 0.05 to about 0.5% in a pharmaceutically acceptable solution, suspension or ointment. Some variation in concentration will necessarily occur, depending on the particular compound employed, the condition of the subject to be treated and the like, and the person responsible for treatment will determine the most suitable concentration for the individual subject.
  • the ophthalmic preparation will preferably be in the form of a sterile aqueous solution containing, if desired, additional ingredients, for example preservatives, buffers, tonicity agents, antioxidants and stabilizers, nonionic wetting or clarifying agents, viscosity-increasing agents and the like.
  • Suitable preservatives include benzalkonium chloride, benzothonium chloride, chlorobutanol, thimerosal and the like.
  • Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borate, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about 6 to 8, preferably between about 7 and 7.5.
  • Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the ophthalmic solution is in the range 0.9 plus or minus 0.2%.
  • Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, thiourea and the like.
  • Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol.
  • Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydromethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like.
  • the ophthalmic preparation will be administered topically to the eye of the subject in need of treatment by conventional methods, for example in the form of drops or by bathing the eye in the ophthalmic solution.
  • the activity of the compounds of the present invention as agents for the control of chronic diabetic complications may be determined by a number of standard biological or pharmacological tests. Suitable tests include (1) measuring their ability to inhibit the enzyme activity of isolated aldose reductase; (2) measuring their ability to reduce or inhibit sorbitol accumulation in the sciatic nerve and lens of acutely streptozotocinized, i.e.
  • diabetic, rats (3) measuring their ability to reverse already-elevated sorbitol levels in the sciatic nerve and lens of chronic streptozotocin-induced diabetic rats; (4) measuring their ability to prevent or inhibit galactitol formation in the lens of acutely galactosemic rats; (5) measuring their ability to delay cataract formation and reduce the severity of lens opacities in chronic galactosemic rats; (6) measuring their ability to prevent sorbitol accumulation and cataract formation in isolated rat lens incubated with glucose; and (7) measuring their ability to reduce already elevated sorbitol levels in isolated rat lens incubated with glucose.
  • Example 1 The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these examples. In the examples, melting points are uncorrected. Example 1
  • Example 2 The title compound of Example 1 (450 mg, 1 mmol) was added to concentrated sulfuric acid (2 mL) and stirred at room temperature for 30 minutes. The reaction was quenched with ice-water (20 mL) and the resulting solid was collected. The solid was crystallized from benzene to provide the title compound (yield: 270 mg; 68%), m.p. 174°C.
  • Example 2 The title compound of Example 2 (740 mg, 1.74 mmol) was added to trifluoroacetic acid (2 mL) and stirred at room temperature for 30 min. The reaction was quenched with ice-water (15 mL) and the precipitated solid was collected, air-dried and crystallized from benzene to obtain the title compound (yield: 115 mg; 33%), m.p. 162°C.
  • Example 8 The title compound of Example 8 was dissolved in ethanol (20 mL) and hydrazine hydrate (0.6 g, 12 mmol) was added to the solution. After stirring for 4 h at room temperature, the solution was concentrated by removing excess ethanol and the concentrate was triturated with IN hydrochloric acid (10 mL). The resulting solid was collected, air-dried and crystallized from ethanol to obtain the title compound (yield, 0.58 g; 24%), m.p. 114-116°C.
  • the title compound was prepared in 46% yield (11.1 g) according to Example 1A, starting from 3,4,5,6-tetrahydrophthalic anhydride in place of 2,3-dimethylmaleic anhydride (15.2 g, 0.1 mol).
  • This mixture of E and Z isomers was chromatographed over silica gel and eluted with a 9:1 mixture of methylene chloride and ethyl acetate. The less polar E isomer was eluted first. The more polar Z isomer was obtained from later fractions.
  • Example 1B To a solution of the title compound of Example 1B (7.05 g, 29.6 mmol) in DMF (65 ml) was added potassium tert-bitoxide (3.65g, 32.5 mmol) and stirred at ambient temperature for 30 min. Bromoacetonitrile (4.26 g, 35.5 mmol) was added to it and stirring was continued for another
  • the solid was air-dried and then crystallized from a 3:1 mixture of cyclohexane and methylene chloride (6.26g, 76%); mp, 120-123°C.
  • Tables 1-3 include melting point or NMR spectrum for the compounds described.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composés présentant une activité d'inhibition de l'aldose-réductase et répondant à la formule (I), dans laquelle X représente CH2, CH2CH2, -CHCH3 ou (a); Y=O ou S; R1 représente un groupe phényle, benzothiazol-2-yle, benzoxazol-2-yle, benzofuran-2-yle, benzothiophèn-2-yle, thiazopyridin-2-yle, oxazolopyridin-2-yle, 3-phényl-1,2,4-oxadiazol-5-yle, et 5-phényl-1,2,4-oxadiazol-3-yle éventuellement substitué, lesdits groupes substitués étant substitués par au moins un et de préférence deux substituants sélectionnés indépendamment les uns des autres parmi fluor, chlore, brome, méthyle et trifluorométhyle; R2 et R3 sont sélectionnés, indépendamment l'un de l'autre, parmi hydrogène, fluor, chlore, brome, alkyle (C1-4), méthylalkylthio (C1-4), alcoxy (C1-4) et trifluorométhyle, ou forment conjointement avec les atomes de carbone auxquels ils sont liés un groupe W, où W représente (b) ou (c), où p est 1 ou 2 et U1 et U2 représentent indépendamment CH2, O ou S à condition que U1 et U2 ne représentent pas tous les deux O ou S; R4 représente hygrogène ou un groupe précurseur de médicament; ou leur sel pharmaceutiquement acceptable.
EP92910955A 1991-03-28 1992-03-09 Acides acetiques de pyridazinone Withdrawn EP0582643A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28
US676919 2000-10-02

Publications (1)

Publication Number Publication Date
EP0582643A1 true EP0582643A1 (fr) 1994-02-16

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92910955A Withdrawn EP0582643A1 (fr) 1991-03-28 1992-03-09 Acides acetiques de pyridazinone

Country Status (19)

Country Link
EP (1) EP0582643A1 (fr)
JP (1) JPH06500793A (fr)
CN (1) CN1065269A (fr)
AU (1) AU658887B2 (fr)
BR (1) BR9205810A (fr)
CA (1) CA2107104A1 (fr)
CZ (1) CZ387092A3 (fr)
DE (1) DE9290035U1 (fr)
FI (1) FI934222A (fr)
HU (1) HUT67836A (fr)
IE (1) IE920979A1 (fr)
IL (1) IL101325A0 (fr)
MX (1) MX9201414A (fr)
NZ (1) NZ242152A (fr)
PT (1) PT100301A (fr)
TW (1) TW207998B (fr)
WO (1) WO1992017446A2 (fr)
YU (1) YU30392A (fr)
ZA (1) ZA922238B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60204611T2 (de) * 2001-02-28 2006-05-11 Pfizer Products Inc., Groton Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
IL156462A0 (en) 2001-03-30 2004-01-04 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (zh) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9217446A2 *

Also Published As

Publication number Publication date
YU30392A (sh) 1994-11-15
AU1779692A (en) 1992-11-02
HUT67836A (en) 1995-05-29
WO1992017446A3 (fr) 1992-11-26
WO1992017446A2 (fr) 1992-10-15
CN1065269A (zh) 1992-10-14
ZA922238B (en) 1993-09-27
AU658887B2 (en) 1995-05-04
JPH06500793A (ja) 1994-01-27
PT100301A (pt) 1993-06-30
CA2107104A1 (fr) 1992-09-29
MX9201414A (es) 1992-10-01
CZ387092A3 (en) 1994-02-16
IE920979A1 (en) 1992-10-07
FI934222A0 (fi) 1993-09-27
HU9302728D0 (en) 1993-12-28
BR9205810A (pt) 1994-06-28
DE9290035U1 (de) 1993-11-18
IL101325A0 (en) 1992-11-15
TW207998B (fr) 1993-06-21
FI934222A (fi) 1993-09-27
NZ242152A (en) 1994-07-26

Similar Documents

Publication Publication Date Title
US4600724A (en) N-naphthoylglycine derivatives
US5268386A (en) Certain 3,4-dihydro 4-oxospiro [2H-1 benzopyrans] useful for treating hyperuricemia
DE69018876T2 (de) Pyridazinon-Derivate.
EP0436307B1 (fr) Acides oxophtalazinylacétiques et leurs analoques
EP0030861A2 (fr) Acides isoquinoléine acétiques et compositions pharmaceutiques les contenant
US5338855A (en) Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses
HU215450B (hu) Eljárás 2,4-dioxo-tiazolidin-származékok előállítására
US4925968A (en) N-acyl-N-naphthoylglycines as aldose reductase inhibitors
WO2001044187A1 (fr) Nouveaux composes tricycliques substitues
EP0582643A1 (fr) Acides acetiques de pyridazinone
EP0041410A1 (fr) Nouveaux éthers tricycliques, leurs procédés de préparation et leur utilisation comme médicament
EP0266102B1 (fr) Dérivés de quinoxalinone
EP0182499B1 (fr) N-(6-Méthoxy-5(perfluoroalcoyl)-1-naphtoyl)-N-méthylglycines et N-(6-méthoxy-5-(perfluoroalcoyl)-1-thionaphthoyl)-N-méthylglycines
DE69625795T2 (de) Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
EP0091761B1 (fr) Dérivés de thiazolidine et leur préparation
US4843062A (en) N-acyl-N-napthoylglycines as aldose reductase inhibitors
US4457939A (en) Aldose reductase inhibiting 5-(2-alkoxy-3-substituted phenyl)hydantoins
KR860001507B1 (ko) 5-(치환된 페닐) 히단토인의 제조방법
EP0112620B1 (fr) Hydantoines-5-(phényl substitués)
CA1188318A (fr) Derives de la n-(naphtoyle substitue) glycine
DE19711617A1 (de) Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CA1187093A (fr) Derives de n-(naphtoyl substitue)glycine
EP0568540A1 (fr) ACIDES ACETIQUES 2,4-DIOXO-PYRIDO 2,3-d] PYRIMIDINE-3- AINSI QUE LEURS ESTERS ET LEURS SELS
FR2473517A1 (fr) Derives d'acide carbothioique de mercaptoacyl amino acides a action anti-hypertensive et leur procede de preparation
BE886513A (fr) Derives de l'ergoline, procede pour les preparer et leur emploi comme medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19961001